190,536 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 190,536 shares of Vanda Pharmaceuticals Inc., valued at approximately $875,000, during the 1st quarter. This acquisition represents about 0.32% ownership in the company.
• Wall Street analysts have varying views on Vanda Pharmaceuticals, with HC Wainwright rating it as a "buy" with a target of $20, while Wall Street Zen downgraded it to a "strong sell."
• Vanda Pharmaceuticals reported an earnings miss in its latest quarterly results, with an EPS of ($0.46), and is anticipated to post -1.12 EPS for the current fiscal year.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 190,536 shares of the biopharmaceutical company's stock, valued at approximately $875,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.32% of Vanda Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in VNDA. American Century Companies Inc. lifted its position in Vanda Pharmaceuticals by 2.1% in the 4th quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company's stock valued at $1,438,000 after acquiring an additional 6,079 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Vanda Pharmaceuticals by 108.9% in the 4th quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company's stock valued at $1,608,000 after acquiring an additional 175,019 shares in the last quarter. Norges Bank bought a new position in Vanda Pharmaceuticals in the 4th quarter valued at approximately $551,000. Brandywine Global Investment Management LLC lifted its position in Vanda Pharmaceuticals by 13.9% in the 4th quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company's stock valued at $189,000 after acquiring an additional 4,820 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Vanda Pharmaceuticals by 12.7% in the 4th quarter. Wellington Management Group LLP now owns 348,846 shares of the biopharmaceutical company's stock valued at $1,671,000 after acquiring an additional 39,195 shares in the last quarter. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Stock Down 1.3%

NASDAQ:VNDA traded down $0.06 on Tuesday, reaching $4.21. 197,769 shares of the company's stock traded hands, compared to its average volume of 575,077. The stock has a 50-day simple moving average of $4.64 and a 200-day simple moving average of $4.54. The firm has a market cap of $247.82 million, a PE ratio of -3.72 and a beta of 0.72. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $5.55.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.12). The business had revenue of $52.59 million for the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. On average, equities analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Insider Transactions at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 7,000 shares of Vanda Pharmaceuticals stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $4.59, for a total value of $32,130.00. Following the completion of the transaction, the director owned 97,082 shares in the company, valued at approximately $445,606.38. This trade represents a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Mihael Hristos Polymeropoulos purchased 20,000 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was bought at an average price of $4.22 per share, with a total value of $84,400.00. Following the transaction, the chief executive officer owned 2,315,731 shares of the company's stock, valued at $9,772,384.82. This represents a 0.87% increase in their position. The disclosure for this purchase can be found here. Company insiders own 10.00% of the company's stock.

Analyst Ratings Changes

VNDA has been the topic of a number of research reports. Wall Street Zen downgraded Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Saturday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.